AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.

Core Viewpoint - AbbVie reported better-than-expected adjusted earnings and revenue for the third quarter, but the stock declined due to mixed results across its drug portfolios [2][3]. Financial Performance - Adjusted earnings were $1.86 per share, exceeding the $1.77 consensus among analysts [3][6]. - Net revenue grew by 9.1% to $15.78 billion, slightly above the expected $15.59 billion [3][6]. Portfolio Performance - Revenue from the immunology portfolio increased by 12%, while the neuroscience portfolio saw a 20% increase [4][6]. - Revenue from the oncology portfolio declined by 0.3% to $1.682 billion [5][6]. - The aesthetics portfolio, which includes Botox Cosmetic, fell by 3.7% to $1.193 billion [5][7]. Product Highlights - Sales of the blockbuster biologic drugs Skyrizi and Rinvoq increased by double digits compared to the same period last year [4]. - Revenue from the anti-inflammatory drug Humira dropped by 55% to $993 million due to competition from cheaper biosimilars after losing exclusivity in 2023 [5][6]. Future Guidance - AbbVie raised its adjusted earnings guidance for 2025 to a range of $10.61 to $10.65 per share, up from a previous range of $10.38 to $10.58 [6][7]. - The company announced a 5.5% increase in its quarterly cash dividend to $1.73 per share, effective February 17, 2026 [8].